ArticlePLOS global public health2025
Diabetes Mellitus screening and associated factors in Peru: A cross-sectional analysis of a national health survey.
Article in PLOS global public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Screening rates for Type 2 diabetes mellitus (T2DM) in Peru remain low despite an increasing prevalence of the disease. In 2022, the American Diabetes Association (ADA) recommended screening adults aged 18-34 with overweight or obesity and at least one risk factor, including Latino ethnicity and lowered the universal screening age to 35 years. This study aimed to determine the T2DM screening prevalence in Peru and the factors associated with lack of screening in the population that meets ADA screening criteria. A cross-sectional, secondary data analysis was conducted based on the 2022 Peruvian Demographic and Health Survey database. Screening was defined as apparently healthy individuals having their blood glucose measured in the last year. Participants aged 18-34 years with overweight or obesity, as well as all participants aged ≥ 35 years, were included. Bivariate analysis was performed using the chi-squared test, and multivariate Poisson regression was used to estimate prevalence ratios (PRs), adjusting for potential confounders. Of 26,166 individuals who met inclusion criteria, 25.3% were screened for T2DM. The factors most strongly associated with lack of screening were: age 18-34 years (aPR: 1.08; 95% CI: 1.05-1.11), having only elementary education (aPR: 1.18; 95% CI: 1.13-1.23), not having health insurance (aPR: 1.15; 95% CI: 1.12-1.18), belonging to the lowest wealth quintile (aPR: 1.09; 95% CI: 1.05-1.13), and daily smoking (aPR: 1.10; 95% CI: 1.01-1.19). The national rate of screening for T2DM in Peru is low (25.3%). There is a higher prevalence for a lack of screening in people who: are younger, have only primary education, do not have health insurance, belong to the lowest wealth quintile, and are smokers. Targeted interventions are needed to improve screening coverage in these high-risk populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.